Saudi Arabia Interventional Cardiology Devices Market Size & Outlook
The interventional cardiology devices market in Saudi Arabia is expected to reach a projected revenue of US$ 39.6 million by 2033. A compound annual growth rate of 2% is expected of Saudi Arabia interventional cardiology devices market from 2026 to 2033.
Saudi Arabia interventional cardiology devices market highlights
The Saudi Arabia interventional cardiology devices market generated a revenue of USD 33.6 million in 2025 and is expected to reach USD 39.6 million by 2033.
The Saudi Arabia market is expected to grow at a CAGR of 2% from 2026 to 2033.
In terms of segment, coronary stents was the largest revenue generating products in 2025.
Intravascular Imaging Catheters and Pressure Guidewires is the most lucrative products segment registering the fastest growth during the forecast period.
Interventional cardiology devices market data book summary
Market revenue in 2025
USD 33.6 million
Market revenue in 2033
USD 39.6 million
Growth rate
2% (CAGR from 2026 to 2033)
Largest segment
Coronary stents
Fastest growing segment
Intravascular Imaging Catheters and Pressure Guidewires
Abbott Laboratories, Medtronic PLC, Boston Scientific Corp, Koninklijke Philips NV, Cardinal Health Inc, Terumo Corp, Teleflex Inc, B. Braun, Biosensors, BIOTRONIK, Asahi Intecc Co Ltd, Cook Medical, Merit Medical Systems Inc, Haemonetics Corp, Vascular Solutions, Zeon Corp, Alvimedica, Meril Life, Medinol
Other key industry trends
In terms of revenue, Saudi Arabia accounted for 0.3% of the global interventional cardiology devices market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Middle East & Africa, South Africa interventional cardiology devices market is projected to lead the regional market in terms of revenue in 2033.
South Africa is the fastest growing regional market in Middle East & Africa and is projected to reach USD 69.5 million by 2033.
Increasing healthcare expenditure with growing number of hospitals and rising target population across the country is expected to contribute to market growth. For instance, in September 2023, an article by Cardiac Interventions highlighted a review of TARGET IV trial for Firehawk rapamycin-eluting coronary stent made from cobalt chromium.
The first three trials have shown promising results among patient populations across 40 countries, including Saudi Arabia. According to a recent article released by Saudi Food and Drug Authority (SFDA), the Paclitaxel eluting stent and Paclitaxel coated balloon products were examined in a postmarket evaluation in Saudi Arabia by international regulatory offices and specialized societies.
Moreover, the SFDA took the initiative to evaluate the safety of Paclitaxel eluting stent and Paclitaxel coated balloon with reference to recent accumulated clinical data, which revealed that they carry the risk of long-term mortality. However, more studies are required when it is compared to noncoated devices.
Saudi Arabia Interventional Cardiology Devices Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Interventional Cardiology Devices Market Outlook will help companies and investors design strategic landscapes.
Coronary Stents was the largest segment with a revenue share of 48.51% in 2025.
Horizon Databook has segmented the Saudi Arabia interventional cardiology devices market based on coronary stents, ptca balloon catheters, intravascular imaging catheters and pressure guidewires, accessory devices covering the revenue growth of each sub-segment from 2021 to 2033.
Increasing healthcare expenditure with growing number of hospitals and rising target population across the country is expected to contribute to market growth. For instance, in September 2023, an article by Cardiac Interventions highlighted a review of TARGET IV trial for Firehawk rapamycin-eluting coronary stent made from cobalt chromium.
The first three trials have shown promising results among patient populations across 40 countries, including Saudi Arabia. According to a recent article released by Saudi Food and Drug Authority (SFDA), the Paclitaxel eluting stent and Paclitaxel coated balloon products were examined in a postmarket evaluation in Saudi Arabia by international regulatory offices and specialized societies.
Moreover, the SFDA took the initiative to evaluate the safety of Paclitaxel eluting stent and Paclitaxel coated balloon with reference to recent accumulated clinical data, which revealed that they carry the risk of long-term mortality. However, more studies are required when it is compared to noncoated devices.
Saudi Arabia Interventional Cardiology Devices Market Products Outlook (Revenue, USD Million , 2021-2033)
Coronary Stents
PTCA Balloon Catheters
Intravascular Imaging Catheters and Pressure Guidewires
Accessory Devices
Saudi Arabia Interventional Cardiology Devices Market Procedures Outlook (Revenue, USD Million , 2021-2033)
Coronary Artery Disease (CAD)
Acute Myocardial Infarction (AMI)
Chronic Total Occlusion (CTO)
Saudi Arabia Interventional Cardiology Devices Market End Use Outlook (Revenue, USD Million , 2021-2033)
Hospitals
Cath Labs
Ambulatory Surgical Centers (ASCs)
Specialty Cardiac Centers
Reasons to subscribe to Interventional Cardiology Devices Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Interventional Cardiology Devices Market Outlook databook
Our clientele includes a mix of Interventional Cardiology Devices Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia Interventional Cardiology Devices Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia Interventional Cardiology Devices Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Saudi Arabia Interventional Cardiology Devices Market, 2021-2033 (US$M)